Biologics for Digestive System/ GI: 89.4% of denials overturned
In 132 California IMR decisions from 2012 to 2025, reviewers overturned 118 (89.4%). In the last five years: 89.7% of 107. 120 were medical-necessity disputes, 12 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 19 | 100.0% |
| 2022 | 19 | 73.7% |
| 2023 | 11 | 100.0% |
| 2024 | 12 | 83.3% |
| 2025 | 46 | 91.3% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 59 | 91.5% | 89.4% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 54 | 94.4% | 89.4% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 37 | 86.5% | 89.4% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 8 | 87.5% | 89.4% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 3 | 33.3% | 89.4% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 3 | 66.7% | 89.4% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that the patient’s parent has requested authorization and coverage for Tremfya. The submitted documentation supports the medical necessity of the requested Tremfya (guselkumab) for this patient with worsening plaque psoriasis, particularly given the paradoxical worsening of psoriasis following infliximab initiation for Crohn’s disease. Tumor necrosis factor (TNF) inhibitors paradoxically induce or worsen psoriasis in approximately 10% …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient’s parent has requested authorization and coverage for Stelera (ustekinumab). Systematic reviews demonstrate clinical remission rates of 40% to 64% at one year in children with refractory Crohn's disease using ustekinumab, and multiple pediatric cohort studies confirm its efficacy and a reasonable safety profile. Per the medical records, the …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for a dosage escalation of Remicade, to 800 mg (10 mg/kg) every eight weeks. Remicade is U.S. Food and Drug Administration-approved and recommended for the treatment of ulcerative colitis. The American College of Gastroenterology guidelines for management of ulcerative colitis support an increase …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:The parent of an enrollee has requested authorization and coverage for a medication regimen to be used in combination with an already approved therapy for Crohn’s disease. There is limited published evidence regarding the safety and efficacy of combination therapy using multiple advanced agents, and available data suggest a potential for …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials for Digestive System/ GI overturned?
In 132 California IMR decisions from 2012 to 2025, reviewers overturned 118 (89.4%). In the last five years: 89.7% of 107. 120 were medical-necessity disputes, 12 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.